Researchers examined the ability of three different G-protein-coupled receptor (GPCR) agonists to reverse signaling inhibition and ameliorate rash induced by epidermal growth factor receptor inhibitors (EGFRi).
[Acta Pharmacologica Sinica]
Sorry, but the selected Zotpress account can't be found.
